Clinical trials: COVID-19; Immunity
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to…
- Trial name
- NCT06374394
- Testing
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2 Acute Respiratory Disease
Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population
The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210 million cases worldwide as of September 1, 2021.
- Trial name
- COVCAL (NCT05135585)
- Testing
- Blood sample collection, Questionnaires
- Where
- 3 sites in New Caledonia
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
COVID-19 Immunity Assessment
The purpose of this study is to collect blood specimens from individuals post infection or post vaccination over time to assess COVID19 Immunity.
- Trial name
- NCT05080231
- Where
- United States
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- DxTerity Diagnostics
Coronavirus Disease 2019
Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Popular topic: Clinical study on immunogenicity and safety evaluation of sequentially enhanced immunity with recombinant Novel Coronavirus vaccine (CHO cells) Research purpose:Main purpose:To evaluate the immunogenicity of…
- Trial name
- NCT05089045
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
SARS-CoV-2
Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1.
- Trial name
- NCT04639375
- Testing
- Vaccinated with polio vaccine (IPV)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- E-MO Biology Inc
COVID-19
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults…
- Trial name
- NCT05972993
- Testing
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg
- Where
- 4 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Influenza, Human+COVID-19
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection.
- Trial name
- NCT07464314
- Testing
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
- Where
- 12 sites in United States
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Relapsing Multiple Sclerosis
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a…
- Trial name
- NCT04847596
- Testing
- Ofatumumab, Covid-19 vaccine
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using…
- Trial name
- NCT06919796
- Testing
- COMIRNATY®
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Multiple Sclerosis
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Vaccine responses in patients treated with anti-CD20 antibodies (ocrelizumab and ofatumumab) or S1P receptor modulators (fingolimod and siponimod) were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing…
- Trial name
- NCT05950308
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Covid19
ImmuneRACE - Immune Response Action to COVID-19 Events
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect…
- Trial name
- NCT04494893
- Where
- United States
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
COVID-19
Immune Profiling of COVID19-patients Admitted to ICU
SARS-CoV-2 is the novel coronavirus responsible for COVID-19, coronavirus disease 2019. This new coronavirus was first detected in Wuhan, China in late December 2019.
- Trial name
- IMPROVISE (NCT04473131)
- Testing
- No intervention
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Coronavirus, SARS-CoV-2 Infection
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05633446
- Testing
- PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations)
- Where
- 2 sites in Philippines
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
COVID-19, Immune Response
Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines
This study aims to evaluate whether oral probiotic supplementation can modulate the immune response induced by COVID-19 vaccination.
- Trial name
- NCT07610512
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Grape King Bio Ltd.
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute